Latest Capital Structure News

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.

Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.

Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.

Lac Gold Limited's latest drilling at the Rouyn Gold Project reveals extensive high-grade gold mineralisation, while the acquisition of the historic Golden Patricia Mine adds a significant growth platform. The company ends the quarter with $13.3 million in cash and a clear focus on resource expansion.

Carnaby Resources has agreed to a scheme of arrangement with Evolution Mining, offering shareholders a 60.4% premium and exposure to Evolution’s portfolio, while reporting significant new high-grade copper-gold results at its Greater Duchess project.

Black Cat Syndicate delivered a transformational FY26, doubling gold output to 90,833oz and generating a record $77M operating cashflow in the June quarter, fully recouping its $106M Paulsens acquisition costs.

BLS Pharmaceuticals capped FY2026 with record quarterly revenue and operating cash flow, driven by international expansion and new supply agreements across regulated markets.

Yandal Resources has expanded the Arrakis gold discovery with high-grade mineralisation at depth and confirmed fresh rock gold at Flushing Meadows, underpinning a busy September quarter exploration schedule.

Peak Processing (ASX: PKP) has recorded its first positive Group EBITDA quarter, driven by record beverage production and a significant US manufacturing agreement, marking a pivotal turnaround in FY26.

A major Zenith Minerals shareholder has lodged a formal application with the Takeovers Panel contesting Forrestania Resources’ recommended takeover bid, citing undisclosed material developments and questionable share acquisitions that may have distorted the market for control.

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

Aurora Energy Metals progresses the Aurora Uranium Project with a major drill program imminent under Eagle Nuclear Energy, while broadening its Western Australian footprint with new exploration licences at Mukinbudin.